The Conversation (0)
Medifocus, Inc. (TSXV:MFS,OTCQX:MDFZF) was granted a new patent, EP1581145, by the newly allowed European Patent Office (EPO) patent. The title of the patent, “Thermotherapy Apparatus for the Treatment and Preventions of Cancer in Male and Female Patients and Cosmetic Ablation of Tissue” and is a focused heat apparatus for the treatment and prevention of cancer tissues, specifically breast cancers.
Medifocus, Inc. (TSXV:MFS,OTCQX:MDFZF) was granted a new patent, EP1581145, by the newly allowed European Patent Office (EPO) patent. The title of the patent, “Thermotherapy Apparatus for the Treatment and Preventions of Cancer in Male and Female Patients and Cosmetic Ablation of Tissue” and is a focused heat apparatus for the treatment and prevention of cancer tissues, specifically breast cancers.
As quoted in the press release:
The new patent, EP1581145, was granted by the EPO to John Mon, COO, and Dr. Alan Fenn, co-inventor of the APA focusing technology, and is assigned to Medifocus. The title of the patent is “Thermotherapy Apparatus for the Treatment and Preventions of Cancer in Male and Female Patients and Cosmetic Ablation of Tissue” and is a focused heat apparatus for, not only the treatment, but also the prevention of cancer tissues and, more specifically, breast cancers. Another embodiment of this patent is for the use of the apparatus for the minimal and non-invasive cosmetic applications specifically to destroy and/or melt fatty tissue as a potential to replace traditional invasive liposuction procedures. It can also be used as a potential apparatus to smooth out the contours and dimpling caused by cellulite.
Click here to read the Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) press release
